Here are the 10-K annual reports from Insmed, Inc. (INSM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INSM filings page.
Insmed Incorporated uses this Annual Report to outline its strategy as a global biopharma company focused on respiratory, immunology & inflammation, and neuro & other rare diseases. The company now has two commercial respiratory drugs: ARIKAYCE, an inhaled therapy for MAC lung disease with approvals in the US, Europe and Japan, and BRINSUPRI, an oral treatment for non-cystic fibrosis bronchiectasis approved in the US in August 2025 and by the European Commission in November 2025.
Insmed highlights large addressable markets in bronchiectasis and MAC lung disease and reports positive Phase 3 data for brensocatib (ASPEN) and positive Phase 2 results for TPIP in pulmonary arterial hypertension and PH-ILD, with multiple Phase 3 programs planned in 2026. Early-stage gene therapy programs INS1201 for Duchenne muscular dystrophy and INS1202 for ALS are in Phase 1 trials, while the ARIKAYCE post-marketing ENCORE study is fully enrolled with topline data expected by April 2026 to support potential full US approval and label expansion.